Tharimmune, Inc.
THAR • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$139.94M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 5.29Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: Mar 31, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.00
Change0.00%
Market Cap$139.94M
52W Range0.95 - 9.08
Beta1.45
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio5.29
Quick Ratio5.29
Volume358.85K
Price$0.00
Change0.00%
Market Cap$139.94M
52W Range0.95 - 9.08
Beta1.45
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio5.29
Quick Ratio5.29
Volume358.85K
Avg Volume807.86K
EPS Surprise-0.37
Investment DNA
How strong this company looks for long-term investors
47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 5.29Weak profitability
Analyst view
No analyst data available now.
🧾
No insider activity
No recent insider transactions available.